LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
−1.45%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.32
- Revenue estimate
- $219.0K
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.32
- EPS estimate
- -$0.40
- Revenue actual
- $190.1K
- Revenue estimate
- $213.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +13.3%
- Revenue beats (12Q)
- 3
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026